MarketPulse

enzyme replacement therapy

3 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Researchandmarkets.Com

Lamzede Market Poised for Expansion as Rare Disease Treatments Gain Momentum

Lamzede market expands globally, led by Europe with fastest growth in Asia-Pacific, driven by rare disease diagnostic advances and enzyme replacement therapy adoption.
REGNpersonalized medicinebiotechnology
GlobeNewswire Inc.GlobeNewswire Inc.··Chiesi Global Rare Diseases / Protalix Biotherapeutics

Elfabrio Wins EU Approval for Less-Frequent Dosing, Triggering $25M Payment

European Commission approves every-4-weeks dosing regimen for Elfabrio, reducing patient treatment burden and triggering $25 million milestone payment to Protalix from Chiesi.
PLXrare diseaseEuropean Commission approval
GlobeNewswire Inc.GlobeNewswire Inc.··Researchandmarkets.Com

Skeletal Dysplasia Market Set to Surge 54% to $5.37B by 2032

Global skeletal dysplasia market projected to grow from $3.48B (2026) to $5.37B (2032) at 7.42% CAGR, driven by diagnostic advances and innovative therapies.
PFENVSRAREREGNBMRNrare diseasebiologic therapy